BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 34215190)

  • 1. Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis.
    Rattanavipanon W; Sotananusak T; Yamaae F; Chandrsawang A; Kaewkan P; Nathisuwan S; Yingchoncharoen T
    BMC Cardiovasc Disord; 2021 Jul; 21(1):324. PubMed ID: 34215190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan.
    Hsiao FC; Wang CL; Chang PC; Lu YY; Huang CY; Chu PH
    J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):152-157. PubMed ID: 31514513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.
    Greene SJ; Choi S; Lippmann SJ; Mentz RJ; Greiner MA; Hardy NC; Hammill BG; Luo N; Samsky MD; Heidenreich PA; Laskey WK; Yancy CW; Peterson PN; Curtis LH; Hernandez AF; Fonarow GC; O'Brien EC
    J Am Heart Assoc; 2021 Aug; 10(16):e021459. PubMed ID: 34350772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching from ramipril to sacubitril/valsartan favorably alters electrocardiographic indices of ventricular repolarization in heart failure with reduced ejection fraction.
    Okutucu S; Sabanoglu C; Yetis Sayin B; Aksoy H; Bursa N; Oto A
    Acta Cardiol; 2020 Feb; 75(1):20-25. PubMed ID: 30513267
    [No Abstract]   [Full Text] [Related]  

  • 5. Sacubitril/valsartan use in a real-world population of patients with heart failure and reduced ejection fraction.
    Mapelli M; Salvioni E; de Martino F; Mattavelli I; Bonomi A; Sassi V; Gugliandolo P; Vignati C; Magini A; Rovai S; Paolillo S; Agostoni P
    J Cardiovasc Med (Hagerstown); 2020 Nov; 21(11):882-888. PubMed ID: 32740412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do the remodeling effects of sacubitril/valsartan treatment depend upon heart failure duration?
    Villani A; Ravaro S; Cerea P; Caravita S; Ciambellotti F; Branzi G; Munforti C; Parati G; Malfatto G
    J Cardiovasc Med (Hagerstown); 2020 Sep; 21(9):682-687. PubMed ID: 32744827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan.
    Sokos GG; Raina A
    Vasc Health Risk Manag; 2020; 16():41-51. PubMed ID: 32021227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenomics of angiotensin receptor/neprilysin inhibitor and its long-term side effects.
    Krittanawong C; Kitai T
    Cardiovasc Ther; 2017 Aug; 35(4):. PubMed ID: 28489317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of the Combination of Sacubitril/Valsartan and SGLT2i in HFrEF Patients (SECSI Registry).
    Jiménez-Blanco Bravo M; Valle A; Gayán Ordás J; Del Prado Díaz S; Cordero Pereda D; Morillas Climent H; Bascompte Claret R; Seller Moya J; Zamorano Gómez JL; Alonso Salinas GL
    J Cardiovasc Pharmacol; 2021 Nov; 78(5):e662-e668. PubMed ID: 34321396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings.
    Mazza A; Townsend DM; Torin G; Schiavon L; Camerotto A; Rigatelli G; Cuppini S; Minuz P; Rubello D
    Biomed Pharmacother; 2020 Oct; 130():110596. PubMed ID: 34321170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan.
    Mohanty AF; Levitan EB; Dodson JA; Vardeny O; King JB; LaFleur J; He T; Patterson OV; Alba PR; Russo PA; Choi ME; Bress AP
    Circ Heart Fail; 2019 Nov; 12(11):e005691. PubMed ID: 31718321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR).
    Ekici B; Yaman M; Küçük M; Dereli S; Yenerçağ M; Yiğit Z; Baş MM; Karavelioğlu Y; Çakmak HA; Kıvrak T; Özkan H; Altın C; Şabanoğlu C; Demirkan B; Ataş AE; Kılıçaslan F; Altay H; Tengiz İ; Fahri Erkan A; Kılıçaslan B; Olgun FE; Durakoğlugil ME; Alhan A; Zoghi M
    Turk Kardiyol Dern Ars; 2021 Jul; 49(5):357-367. PubMed ID: 34308869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The eligible population of the PARADIGM-HF trial in a real-world outpatient clinic and its cardiovascular risk between 2005 and 2016.
    Chen X; Schaufelberger M; Fu M
    J Cardiovasc Med (Hagerstown); 2020 Jan; 21(1):6-12. PubMed ID: 31789711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial.
    DeVore AD; Mi X; Thomas L; Sharma PP; Albert NM; Butler J; Hernandez AF; Patterson JH; Spertus JA; Williams FB; Duffy CI; McCague K; Fonarow GC
    J Am Heart Assoc; 2018 Jun; 7(12):. PubMed ID: 29895587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States.
    DeVore AD; Hill CL; Thomas L; Sharma PP; Albert NM; Butler J; Patterson JH; Spertus JA; Williams FB; Duffy CI; McCague K; Hernandez AF; Fonarow GC
    Circ Heart Fail; 2018 Sep; 11(9):e005400. PubMed ID: 30354360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of sacubitril/valsartan in patients with heart failure and chronic kidney disease: A meta-analysis.
    Kang H; Zhang J; Zhang X; Qin G; Wang K; Deng Z; Fang Y; Chen G
    Eur J Pharmacol; 2020 Oct; 884():173444. PubMed ID: 32739172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF).
    Okumura N; Jhund PS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJ;
    Circulation; 2016 Jun; 133(23):2254-62. PubMed ID: 27143684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction.
    Fudim M; Sayeed S; Xu H; Matsouaka RA; Heidenreich PA; Velazquez EJ; Yancy CW; Fonarow GC; Hernandez AF; DeVore AD
    Circ Heart Fail; 2020 Apr; 13(4):e006645. PubMed ID: 32248695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.